Avectas is a cell engineering business developing a patented delivery technology platform to enable the ex-vivo manufacture of complex gene modified cell therapy products, which will retain high in-vivo functionality.
Our vision is to be the leading non-viral cell engineering technology, integrated into manufacturing processes for multiple autologous and allogeneic therapies.
Become a Partner
Avectas’ SOLUPORE™ platform offers a cell engineering solution for next generation cell and gene therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene modified cell therapy products.
If you would like to learn more about working with Avectas and our cell engineering technology, get in touch with us.